MAP2K1 and breast carcinoma: 6) The therapeutic markers used for clinical trial matching span a range of levels of evidence, as described in Fig. 1, from predictive markers of clinical significance (eg, EGFR L858R mutation in NSCLC) to hypothetical markers supported by case reports or strong preclinical evidence (eg, MAP2K1 amplification in breast cancer).54 Therefore, confidence in the actionability of the markers with clinical trial matches varies depending on the supporting evidence, which is summarized in the clinical report content.